Unity Biotechnology (STU:9U90) Cash-to-Debt : 1.60 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Unity Biotechnology's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.60.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Unity Biotechnology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Unity Biotechnology's Cash-to-Debt or its related term are showing as below:

STU:9U90' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54 Med: 5000.94 Max: No Debt
Current: 1.6

During the past 8 years, Unity Biotechnology's highest Cash to Debt Ratio was No Debt. The lowest was 1.54. And the median was 5000.94.

STU:9U90's Cash-to-Debt is ranked worse than
70.94% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs STU:9U90: 1.60

Unity Biotechnology Cash-to-Debt Historical Data

The historical data trend for Unity Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Unity Biotechnology Cash-to-Debt Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.54

1.58

1.88

1.60

Unity Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1.88	1.78	1.60	1.88	1.60

Competitive Comparison of Unity Biotechnology's Cash-to-Debt

For the Biotechnology subindustry, Unity Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unity Biotechnology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's Cash-to-Debt falls into.

Unity Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Unity Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.615	/	(3.165	+	21.585)
	=	1.60

Unity Biotechnology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.615	/	(3.165	+	21.585)
	=	1.60

Unity Biotechnology (STU:9U90) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Unity Biotechnology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology (STU:9U90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (STU:9U90) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

UBX:USA 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Unity Biotechnology (STU:9U90) Headlines

No Headlines